EX9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Profitability & Cash GenerationExtremely high margins and very strong cash conversion (FCF ~99% of net income, OCF well above net income) provide durable internal funding for R&D, trials, and capital returns without near-term financing. This underpins operational resilience and strategic optionality over the next 2–6 months.
Commercial Franchise StrengthSustained share gains and double-digit TRx growth indicate durable product adoption and growing first-line footprint. A large, expanding revenue base from cabozantinib supports predictable near-term cash flow and funds pipeline programs while reducing execution dependence on single upcoming events.
Balance Sheet Strength & BuybacksA strong cash position plus aggressive, executed buybacks reflect free-cash-flow confidence and provide shareholder-aligned capital allocation flexibility. Low reliance on debt combined with ample liquidity supports continued investment in pivotal trials and strategic maneuvers over the medium term.
Bears Say
Rising Gross-to-Net PressureHigher discounts, 340B volume, Medicare Part D rebates and increased co-pay support reduce realized revenue per unit. If structural, these deductions can erode net top-line and margin sustainability, constraining reinvestment capacity and making revenue less resilient to future pricing or reimbursement shifts.
Dependence On Pivotal ReadoutsA material portion of future growth hinges on several timing-sensitive pivotal trials and regulatory decisions (including an NDA under review). Delays, immature data, or negative outcomes would materially affect long-term revenue trajectory and product diversification over the coming months.
Shrinking Equity/Asset BaseDeclining equity and assets reduce the balance-sheet cushion and mean ROE improvements partly reflect a smaller equity base. This diminution limits downside absorption and could elevate financial risk if commercial or clinical setbacks occur, reducing long-term balance-sheet durability.
Exelixis News
EX9 FAQ
What was Exelixis’s price range in the past 12 months?
Currently, no data Available
What is Exelixis’s market cap?
Exelixis’s market cap is CHF10.77B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Aug 05, 2026 which is in 2 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on May 05, 2026. The company reported CHF0.703 earnings per share for the quarter, beating the consensus estimate of CHF0.615 by CHF0.087.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.69.
How many shares outstanding does Exelixis have?
Currently, no data Available
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of CHF0.703 in its last earnings report, beating expectations of CHF0.615. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in CH:EX9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF42.27 (― Upside)
CHF42.27 (― Upside)
Blogger Sentiment
Bullish
CH:EX9 Sentiment 82%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF9.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.59%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EX9 Company Deck
EX9 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for CABOMETYX (double-digit global growth, notable TRx and market share gains), solid profitability and cash position, active share repurchases, and substantial advancement of ZANZA with one positive pivotal result (20% OS risk reduction in STELLAR-303 ITT) and multiple ongoing pivotal trials across tumor types. Offsetting these positives were increased gross-to-net deductions (30.2%), a materially higher tax provision, reliance on several upcoming readouts (some immature or timing‑sensitive), and broader development complexity highlighted by a competitive miss in a related triplet program. On balance, operational and commercial strengths and a broad, advancing pipeline materially outweigh the near-term execution and regulatory uncertainties.View all CH:EX9 earnings summariesEX9 Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
